Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

This study has been completed.
Sponsor:
Collaborators:
FKD Therapies Oy of Finland
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01162785
First received: July 13, 2010
Last updated: November 23, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2016
  Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)